Loading...
XSTO
SYNACT
Market cap116mUSD
Dec 05, Last price  
20.55SEK
1D
0.49%
1Q
8.04%
Jan 2017
269.14%
IPO
307.82%
Name

SynAct Pharma AB

Chart & Performance

D1W1MN
XSTO:SYNACT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.67%
Rev. gr., 5y
%
Revenues
0k
Net income
-82m
L-61.82%
-937,000-982,000-15,455,945-15,395,165-23,445,381-23,957,721-26,551,000-69,304,000-99,205,000-215,810,000-82,401,000
CFO
-89m
L-10.96%
00-14,733,613-17,201,772-24,214,950-16,123,518-33,239,000-64,997,000-117,555,000-100,177,000-89,197,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
URL
https://synactpharma.com/
IPO date
Jul 11, 2016
Employees
5
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT